NG2 antigen is a therapeutic target for MLL-rearranged B-cell acute lymphoblastic leukemia

B cell acute lymphoblastic leukemia (B-ALL) is the most common childhood cancer, with cure rates of ∼80%. MLL-rearranged (MLLr) B-ALL (MLLr-B-ALL) has, however, an unfavorable prognosis with common therapy refractoriness and early relapse, and therefore new therapeutic targets are needed for relapse...

Descripción completa

Detalles Bibliográficos
Autores principales: Lopez-Millan, Belen, Sanchéz-Martínez, Diego, Roca-Ho, Heleia, Gutiérrez-Agüera, Francisco, Molina, Oscar, Diaz de la Guardia, Rafael, Torres-Ruiz, Raúl, Fuster, Jose Luís, Ballerini, Paola, Suessbier, Ute, Nombela-Arrieta, Cesar, Bueno, Clara, Menéndez, Pablo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6755967/
https://www.ncbi.nlm.nih.gov/pubmed/30635633
http://dx.doi.org/10.1038/s41375-018-0353-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6755967/
https://www.ncbi.nlm.nih.gov/pubmed/30635633
http://dx.doi.org/10.1038/s41375-018-0353-0

Ejemplares similares